Cat. #151394
Anti-Cytokeratin [PK121]
Cat. #: 151394
Sub-type: Primary antibody
Unit size: 100 ug
Availability: 10-12 weeks
Target: Cytokeratins of 61-62 kDa
Class: Monoclonal
Application: IHC ; WB
Reactivity: Human
Host: Mouse
£300.00
This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.
Contributor
Inventor: Karen Pulford
Institute: University of Oxford
Tool Details
*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)
- Name: Anti-Cytokeratin [PK121]
- Research fields: Cancer;Cell biology;Cell signaling and signal transduction
- Clone: PK121
- Tool sub type: Primary antibody
- Class: Monoclonal
- Conjugation: Unconjugated
- Molecular weight: 61-62 kDa
- Reactivity: Human
- Host: Mouse
- Application: IHC ; WB
- Description: Keratins are a family of intermediate filament proteins that assemble into filaments through forming heterodimers of one type I keratin (keratins 9 to 23) and one type II keratin (keratins 1 to 8). Keratins demonstrate tissue and differentiation specific expression profiles.
- Immunogen: Epidermal keratin
- Isotype: IgG
- Myeloma used: P3/NS1/1-Ag4.1
Target Details
- Target: Cytokeratins of 61-62 kDa
- Molecular weight: 61-62 kDa
- Target background: Keratins are a family of intermediate filament proteins that assemble into filaments through forming heterodimers of one type I keratin (keratins 9 to 23) and one type II keratin (keratins 1 to 8). Keratins demonstrate tissue and differentiation specific expression profiles.
Applications
- Application: IHC ; WB
Handling
- Format: Liquid
- Concentration: 0.9-1.1 mg/ml
- Unit size: 100 ug
- Storage buffer: PBS with 0.02% azide
- Storage conditions: -15° C to -25° C
- Shipping conditions: Dry ice
References
- Gatter et al. 1985. J Clin Pathol. 38(12):1353-7. PMID: 3908491.
- An immunocytochemical study of malignant melanoma and its differential diagnosis from other malignant tumours.
